SH3BP5-driven metabolic-immune crosstalk in DLBCL: a prognostic biomarker and therapeutic target for reshaping immunosuppressive microenvironment
The study was registered in the Chinese Clinical Trial Registry (ChiCTR2200060430; http://www.chictr.org.cn/ ) on June 1, 2022.
Authors
- Yinyin Xie (ORCID: https://orcid.org/0000-0002-5858-3873)
- Yuan Zong (ORCID: https://orcid.org/0000-0003-0576-6614)
- Yi Yang (ORCID: https://orcid.org/0000-0001-9044-0277)
- Lei Li (ORCID: https://orcid.org/0000-0002-3717-4464)
- Ning Li (ORCID: https://orcid.org/0000-0003-1025-9641)
- Xiaoyu Zhao (ORCID: https://orcid.org/0000-0001-5095-7212)
- Liting Jiang (ORCID: https://orcid.org/0000-0002-2342-2017)
- Tong Wu (ORCID: https://orcid.org/0000-0002-4005-3479)
- Jiawen Zhao (ORCID: https://orcid.org/0000-0003-2917-8630)
- Yiming Gao (ORCID: https://orcid.org/0000-0002-9568-7268)
Institutions
- Shanghai Jiao Tong University (CN)
- Ruijin Hospital (CN)
- Shanghai Institute of Hematology (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-09-24
- DOI
- https://doi.org/10.1186/s12967-025-06951-z
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00